Literature DB >> 10810296

Transgenic mice expressing bovine GH develop arthritic disorder and self-antibodies.

S Ogueta1, I Olazabal, I Santos, E Delgado-Baeza, J P García-Ruiz.   

Abstract

We observed disability of movement in 6-month-old transgenic mice expressing the fusion gene coding for the bovine GH (bGH) under the transcriptional control of phosphoenolpyruvate carboxykinase promoter (PEPCK-bGH). Histological study of the knee joint showed altered synovial and tibial articular cartilage tissues. In the cartilage the following observations were made: (i) generalized loss of the normal zonal structure and presence of clefts, and (ii) profound alterations in chondrocyte growth/differentiation processes consistent with hypertrophy. The synovial tissue showed a reduced number of adipocytes, and a significant thickening of synovial lining tissue and pannus. These findings indicate that transgenic mice suffer damage to diarthritic joints with osteoarthritic appearance. As changes in synovial membrane in osteoarthritis are almost indistinguishable from those seen in inflammatory arthritis, we determined the potential correlation with an immunological disorder. Serological determination of self-antibodies measured as a function of age and sex showed anti-nuclear, anti-single-stranded DNA, anti-double-stranded DNA and anti-70K antibodies, and an altered immunoglobulin typing. These results suggest that transgenic mice expressing bGH develop an arthritic process which is correlated with an immune disorder. The results also indicate that these mice are a suitable animal model to study the specific role of GH-driven processes in immune cells and arthritis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810296     DOI: 10.1677/joe.0.1650321

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Identification of differentially expressed genes in the kidneys of growth hormone transgenic mice.

Authors:  K T Coschigano; A N Wetzel; N Obichere; A Sharma; S Lee; R Rasch; M M Guigneaux; A Flyvbjerg; T G Wood; J J Kopchick
Journal:  Growth Horm IGF Res       Date:  2010-07-23       Impact factor: 2.372

Review 2.  Mouse models of growth hormone action and aging: a proteomic perspective.

Authors:  Juan Ding; Lucila Sackmann-Sala; John J Kopchick
Journal:  Proteomics       Date:  2012-11-26       Impact factor: 3.984

3.  WISP3, the gene responsible for the human skeletal disease progressive pseudorheumatoid dysplasia, is not essential for skeletal function in mice.

Authors:  Wendy E Kutz; Yaoqin Gong; Matthew L Warman
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

4.  Effects of overexpression of growth hormone on T cell activity in transgenic mice.

Authors:  A I Esquifino; A Arce; M P Alvarez; A Szary; H Brown-Borg; A Bartke
Journal:  J Physiol Biochem       Date:  2002-09       Impact factor: 4.158

Review 5.  Mice with gene alterations in the GH and IGF family.

Authors:  Yanrong Qian; Darlene E Berryman; Reetobrata Basu; Edward O List; Shigeru Okada; Jonathan A Young; Elizabeth A Jensen; Stephen R C Bell; Prateek Kulkarni; Silvana Duran-Ortiz; Patricia Mora-Criollo; Samuel C Mathes; Alison L Brittain; Mat Buchman; Emily Davis; Kevin R Funk; Jolie Bogart; Diego Ibarra; Isaac Mendez-Gibson; Julie Slyby; Joseph Terry; John J Kopchick
Journal:  Pituitary       Date:  2021-11-19       Impact factor: 4.107

6.  Development of human mesenchymal stem cells on DC sputtered titanium nitride thin films.

Authors:  M Manso-Silvan; J M Martínez-Duart; S Ogueta; P García-Ruiz; J Pérez-Rigueiro
Journal:  J Mater Sci Mater Med       Date:  2002-03       Impact factor: 3.896

7.  Inhibitory Role of Growth Hormone in the Induction and Progression Phases of Collagen-Induced Arthritis.

Authors:  Ricardo Villares; Gabriel Criado; Yasmina Juarranz; Mercedes Lopez-Santalla; Eva M García-Cuesta; José M Rodríguez-Frade; Javier Leceta; Pilar Lucas; José Luis Pablos; Carlos Martínez-A; Marina I Garin; Rosa P Gomariz; Mario Mellado
Journal:  Front Immunol       Date:  2018-05-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.